DOCSLIB.ORG

Specialty Pharmacy Medications

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Specialty Pharmacy Medications Specialty Medications, Attachment A Effective 11/14/2018 Brand Name Generic Name ACTEMRA Tocilizumab injection ACTHAR H.P. Repository Corticotropin injection ACTIMMUNE Interferon Gamma-1b injection ADAGEN pegademase bovine injection ADCETRIS brentuximab vedotin injection ALECENSA alectinib hydrochloride capsule ALFERON N interferon alfa-n3 injection AMPYRA dalfampridine tablet, film coated, extended release APOKYN apomorphine hydrochloride injection ARALAST alpha.1-proteinase inhibitor human ARZERRA ofatumumab injection AUBAGIO teriflunomide tablet AVASTIN bevacizumab injection AVEED testosterone undecanoate injection BENDEKA bendamustine hydrochloride injection BENLYSTA belimumab injection BERINERT human c1-esterase inhibitor BETHKIS tobramycin solution for inhalation BOSULIF bosutinib monohydrate tablet BUPHENYL sodium phenylbutyrate tablet, powder CABOMETYX cabozantinib tablet CAYSTON aztreonam solution for inhalation CERDELGA eliglustat capsule COPEGUS ribavirin tablet COSENTYX secukinumab injection COTELLIC cobimetinib tablet CYSTARAN cysteamine hydrochloride ophth soln. DACOGEN decitabine injection DAKLINZA daclatasvir tablet DARAPRIM pyrimethamine tablet DARZALEX daratumumab injection EGRIFTA tesamorelin injection EPCLUSA velpatasvir and sofosbuvir tablet ERGOMAR ergotamine tartrate tablet ERIVEDGE vismodegib capsule ESBRIET pirfenidone capsule & tablets EXJADE deferasirox tablet, for suspension EYLEA aflibercept injection Brand Name Generic Name FARYDAK panobinostat capsule GAZYVA obinutuzumab injection GEL-ONE hyaluronate sod, cross-linked, injection GILOTRIF afatinib tablet GLASSIA alpha-1-proteinase inhibitor (human) injection HARVONI ledipasvir and sofosbuvir tablet HEMANGEOL propranolol hydrochloride oral olution HEMLIBRA Emicizumab-kxwh injection HERCEPTIN trastuzumab injection HETLIOZ tasimelteon capsule HIZENTRA human immunoglobulin g liquid HUMIRA SYRINGEKIT adalimumab injection human immuneglobulin g and hyaluronidase (human HYQVIA recombinant) injection IBRANCE palbociclib capsule ILARIS canakinumab injection ILUVIEN fluocinolone acetonide intravitreal implant INCIVEK telaprevir tablets INCRELEX mecasermin injection INFERGEN interferon alfacon-1 injection INLYTA axitinib tablet INTRON-A interferon alfa-2b injection IRESSA gefitinib tablet JADENU deferasirox tablet JAKAFI ruxolitinib tablet JETREA ocriplasmin injection KADCYLA ado-trastuzumab emtansine injection KALYDECO ivacaftor tablet KANUMA sebelipase alfa injection KITABIS PAK tobramycin solution for inhalation KUVAN sapropterin dihydrochloride tablet and pwd for oral soln. KYLEENA levonorgestrel intrauterine device KYNAMRO mipomersen sodium injection KYPROLIS carfilzomib injection LEMTRADA alemtuzumab injection LETAIRIS ambrisentan tablet LONSURF trifluridine and tipiracil tablet LUCENTIS ranibizumab intravitreal injection LUMIZYME alglucosidase alfa injection LYNPARZA olaparib capsule, tablets Brand Name Generic Name MACUGEN pegaptanib sodium intravitreal injection MAKENA hydroxyprogesterone caproate injection MATULANE procarbazine hydrochloride capsule MAVYRET glecaprevir and pibrentasvir tablet MIRENA levonorgestrel intrauterine device MUGARD glycerine/carb h. polymer A/potassium hydroxide NAGLAZYME galsulfase solution for IV infusion NATPARA parathyroid hormone injection NEXAVAR sorafenib tablet NINLARO ixazomib capsule NORTHERA droxidopa capsule NUCALA mepolizumab injection NUPLAZID pimavanserin tartrate tablet NUTROPIN somatropin injection NUWIQ antihemophilic factor (recombinant) OCALIVA obeticholic acid tablet OCREVUS ocrelizumab injection OFEV nintedanib capsule OLYSIO simeprevir capsule OPSUMIT macitentan tablet ORALAIR allergen pollen extracts, SL tablets ORKAMBI lumacaftor and ivacaftor tablet OTEZLA apremilast tablet PEGASYS peginterferon alfa-2a injection PEG-INTRON peginterferon alfa-2b injection PERJETA pertuzumab injection PLEGRIDY peginterferon beta-1a injection POMALYST pomalidomide capsule PURIXAN purixan oral suspension QUTENZA capsaicin patch RAVICTI glycerol phenylbutyrate oral liquid REVLIMID lenalidomide capsule RIASTAP fibrinogen human injection RIBASPHERE 200 ribavirin capsule RIBAVIRIN ribavirin capsule, tablets RITUXAN rituximab injection RUCONEST c1 esterase inhibitor recombinant injection SABRIL vigabatrin tablet, pwd for susp. SAMSCA tolvaptan tablet Brand Name Generic Name SIMPONI golimumab solution (SQ or IV infusion) SKYLA levonorgestrel intrauterine device SOLESTA dextranomer microspheres/sodium hyaluronate SOLIRIS eculizumab injection SOMAVERT pegvisomant injection SOVALDI sofosbuvir tablet STIVARGA regorafenib tablet SUPPRELIN LA histrelin acetate implant SUTENT sunitinib malate capsule SYLATRON peginterferon alfa-2b injection SYNAGIS palivizumab injection SYNRIBO omacetaxine mepesuccinate injection TAGRISSO osimertinib tablet TALTZ ixekizumab injection TARCEVA erlotinib hydrochloride tablet TECENTRIQ atezolizumab injection TECFIDERA dimethyl fumarate capsule TECHNIVIE ombitasvir/paritaprevir/ritonavir tablets TESTOPEL testosterone pellet THALOMID thalidomide capsule THIOLA tiopronin tablet TOBI tobramycin solution for inhalation TOBI PODHALER tobramycin capsule for inhalation TRACLEER bosentan tablet TYSABRI natalizumab injection VARITHENA polidocanol injection VECAMYL mecamylamine hydrochloride tablet VICTRELIS boceprevir capsule VIEKIRA PAK dasabuvir tablets and ombitasvir,/paritaprevir/ritonavir tablets VIGABATRIN Vigabatrin powder packet for oral solution VIMIZIM elosulfase alfa injection VISUDYNE verteporfin for injection VOSEVI sofosbuvir/velpatasvir/voxilaprevir tablet VPRIV velaglucerase alfa injection XALKORI crizotinib capsule XENAZINE tetrabenazine tablet XOLAIR omalizumab injection XTANDI enzalutamide capsule YERVOY ipilimumab injection Brand Name Generic Name YONDELIS trabectedin injection ZEPATIER elbasvir/grazoprevir tablet ZELBORAF vemurafenib tablet ZINBRYTA daclizumab injection ZYKADIA ceritinib capsule ZYTIGA abiraterone acetate tablet .
Load more

Recommended publications
  • Intravenous Enzyme Replacement Therapy (ERT) for Gaucher Disease
    UnitedHealthcare® Commercial Medical Benefit Drug Policy Intravenous Enzyme Replacement Therapy (ERT) for Gaucher Disease Policy Number: 2021D0048K Effective Date: April 1, 2021 Instructions for Use Table of Contents Page Related Commercial Policy Coverage Rationale ....................................................................... 1 • Provider Administered Drugs – Site of Care Applicable Codes .......................................................................... 3 Background.................................................................................... 3 Community Plan Policy Benefit Considerations .................................................................. 3 • Intravenous Enzyme Replacement Therapy (ERT) Clinical Evidence ........................................................................... 4 for Gaucher Disease U.S. Food and Drug Administration ............................................. 6 Centers for Medicare and Medicaid Services ............................. 6 References ..................................................................................... 7 Policy History/Revision Information ............................................. 8 Instructions for Use ....................................................................... 8 Coverage Rationale See Benefit Considerations This policy refers to the following drug products, all of which are intravenous enzyme replacement therapies used in the treatment of Gaucher disease: Cerezyme® (imiglucerase) Elelyso® (taliglucerase) VPRIV® (velaglucerase)
    [Show full text]
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • WO 2017/173059 Al 5 October 2017 (05.10.2017) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2017/173059 Al 5 October 2017 (05.10.2017) P O P C T (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, C12N 9/26 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (21) International Application Number: KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, PCT/US20 17/024981 MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (22) International Filing Date: NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, 30 March 2017 (30.03.2017) RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (25) Filing Language: English ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 62/3 15,400 30 March 2016 (30.03.2016) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/457,584 10 February 2017 (10.02.2017) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 15/473,994 30 March 2017 (30.03.2017) US TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (71) Applicant: AMICUS THERAPEUTICS, INC.
    [Show full text]
  • Enzyme Replacement Therapy Srx-0019 Policy Type ☒ Medical ☐ Administrative ☐ Payment
    MEDICAL POLICY STATEMENT Original Effective Date Next Annual Review Date Last Review / Revision Date 06/15/2011 03/15/2017 10/04/2016 Policy Name Policy Number Enzyme Replacement Therapy SRx-0019 Policy Type ☒ Medical ☐ Administrative ☐ Payment Medical Policy Statements prepared by CSMG Co. and its affiliates (including CareSource) are derived from literature based on and supported by clinical guidelines, nationally recognized utilization and technology assessment guidelines, other medical management industry standards, and published MCO clinical policy guidelines. Medically necessary services include, but are not limited to, those health care services or supplies that are proper and necessary for the diagnosis or treatment of disease, illness, or injury and without which the patient can be expected to suffer prolonged, increased or new morbidity, impairment of function, dysfunction of a body organ or part, or significant pain and discomfort. These services meet the standards of good medical practice in the local area, are the lowest cost alternative, and are not provided mainly for the convenience of the member or provider. Medically necessary services also include those services defined in any Evidence of Coverage documents, Medical Policy Statements, Provider Manuals, Member Handbooks, and/or other policies and procedures. Medical Policy Statements prepared by CSMG Co. and its affiliates (including CareSource) do not ensure an authorization or payment of services. Please refer to the plan contract (often referred to as the Evidence of Coverage) for the service(s) referenced in the Medical Policy Statement. If there is a conflict between the Medical Policy Statement and the plan contract (i.e., Evidence of Coverage), then the plan contract (i.e., Evidence of Coverage) will be the controlling document used to make the determination.
    [Show full text]
  • BCBSVT Specialty Drug List Effective 2021.07.01.Xlsx
    Effective Date: 07/01/2021 SPECIALTY DRUG LIST Revised Date: 05/07/2021 DOSAGE EXCLUDED ON NATIONAL DRUG CLASS DRUG NAME GENERIC NAME FORM PERFORMANCE FORMULARY ANEMIA ARANESP SOLN DARBEPOETIN ALFA SOLN INJ ANEMIA ARANESP SOSY DARBEPOETIN ALFA SOLN PREFILLED SYRINGE ANEMIA EPOGEN SOLN EPOETIN ALFA INJ X ANEMIA PROCRIT SOLN EPOETIN ALFA INJ X ANEMIA REBLOZYL SOLR LUSPATERCEPT-AAMT FOR SUBCUTANEOUS INJ ANEMIA RETACRIT SOLN EPOETIN ALFA-EPBX INJ ANTI-GOUT AGENT KRYSTEXXA SOLN PEGLOTICASE INJ (FOR IV INFUSION) ANTI-INFECTIVE PREVYMIS SOLN LETERMOVIR IV SOLN ANTI-INFECTIVE PREVYMIS TABS LETERMOVIR TAB ASTHMA CINQAIR SOLN RESLIZUMAB IV INFUSION SOLN ASTHMA FASENRA SOSY BENRALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE ASTHMA FASENRA PEN SOAJ BENRALIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR ASTHMA NUCALA SOAJ MEPOLIZUMAB SUBCUTANEOUS SOLUTION AUTO-INJECTOR ASTHMA NUCALA SOLR MEPOLIZUMAB FOR INJ ASTHMA NUCALA SOSY MEPOLIZUMAB SUBCUTANEOUS SOLUTION PREF SYRINGE ASTHMA XOLAIR SOLR OMALIZUMAB FOR INJ ASTHMA XOLAIR SOSY OMALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE CARDIOVASCULAR VYNDAMAX CAPS TAFAMIDIS CAP CARDIOVASCULAR VYNDAQEL CAPS TAFAMIDIS MEGLUMINE (CARDIAC) CAP CENTRAL NERVOUS SYSTEM AGENTS AUSTEDO TABS DEUTETRABENAZINE TAB CENTRAL NERVOUS SYSTEM AGENTS ENSPRYNG SOSY SATRALIZUMAB-MWGE SUBCUTANEOUS SOLN PREF SYRINGE CENTRAL NERVOUS SYSTEM AGENTS HETLIOZ CAPS TASIMELTEON CAPSULE CENTRAL NERVOUS SYSTEM AGENTS HETLIOZ LQ SUSP TASIMELTEON ORAL SUSP CHEMOTHERAPY PROTECTANT AMIFOSTINE SOLR AMIFOSTINE CRYSTALLINE FOR INJ CHEMOTHERAPY PROTECTANT ELITEK
    [Show full text]
  • Cipaglucosidase Alfa/Miglustat Phase 3 PROPEL Results
    AT-GAA (ATB200/AT2221) Phase 3 PROPEL Topline Results February 11, 2021 Phase 3 PROPEL Topline Results 2 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to top-line data from a global Phase 3 study to investigate AT-GAA for the treatment of Pompe Disease and the potential implications on these data for the future advancement and development of AT-GAA. Words such as, but not limited to, “look forward t o ,” “believe,” “expect,” “anticipate,” “estimate,” “intend,” "confidence," "encouraged," “potential,” “plan,” “targets,” “likely,” “may,” “will,” “would,” “should” and “c o u l d ,” and similar expressions or words identify forward-looking statements. The forward looking statements included in this press release are based on management's current expectations and belief's which are subject to a number of risks, uncertainties and factors, including that the Company will not be able to successfully complete the development of, obtain regulatory approval for, or successfully manufacture and commercialize AT-GAA. In addition, all forward looking statements are subject to the other risks and uncertainties detailed in our Annual Report on Form 10-K for the year ended December 31, 2019 and Quarterly Report on 10-Q for the Quarter ended September 30, 2020. As a consequence, actual results may differ materially from those set forth in this press release. You are cautioned not to place undue reliance on these forward looking statements, which speak only of the date hereof. All forward looking statements are qualified in their entirety by this cautionary statement and we undertake no obligation to revise this press release to reflect events or circumstances after the date hereof.
    [Show full text]
  • Asfotase Alfa (Strensiq) for Treatment of Hypophosphatasia in Infants and Children
    AHRQ Healthcare Horizon Scanning System – Potential High-Impact Interventions Report Priority Area 08: Functional Limitations and Disability Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. HHSA290-2010-00006-C Prepared by: ECRI Institute 5200 Butler Pike Plymouth Meeting, PA 19462 December 2015 Statement of Funding and Purpose This report incorporates data collected during implementation of the Agency for Healthcare Research and Quality (AHRQ) Healthcare Horizon Scanning System by ECRI Institute under contract to AHRQ, Rockville, MD (Contract No. HHSA290-2010-00006-C). The findings and conclusions in this document are those of the authors, who are responsible for its content, and do not necessarily represent the views of AHRQ. No statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. This report’s content should not be construed as either endorsements or rejections of specific interventions. As topics are entered into the System, individual topic profiles are developed for technologies and programs that appear to be close to diffusion into practice in the United States. Those reports are sent to various experts with clinical, health systems, health administration, and/or research backgrounds for comment and opinions about potential for impact. The comments and opinions received are then considered and synthesized by ECRI Institute to identify interventions that experts deemed, through the comment process, to have potential for high impact. Please see the methods section for more details about this process.
    [Show full text]
  • Myozyme, INN-Alglucosidase Alfa
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Myozyme 50 mg powder for concentrate for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One vial contains 50 mg of alglucosidase alfa. After reconstitution, the solution contains 5 mg of alglucosidase alfa* per ml and after dilution, the concentration varies from 0.5 mg to 4 mg/ml. *Human acid α-glucosidase is produced in Chinese hamster ovary cells (CHO) by recombinant DNA technology. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder for concentrate for solution for infusion. White to off-white powder. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Myozyme is indicated for long-term enzyme replacement therapy (ERT) in patients with a confirmed diagnosis of Pompe disease (acid -glucosidase deficiency). Myozyme is indicated in adults and paediatric patients of all ages. 4.2 Posology and method of administration Myozyme treatment should be supervised by a physician experienced in the management of patients with Pompe disease or other inherited metabolic or neuromuscular diseases. Posology The recommended dose regimen of alglucosidase alfa is 20 mg/kg of body weight administered once every 2 weeks. Patient response to treatment should be routinely evaluated based on a comprehensive evaluation of all clinical manifestations of the disease. Paediatric and older people There is no evidence for special considerations when Myozyme is administered to paediatric patients of all ages or older people. Patients with renal and hepatic impairment The safety and efficacy of Myozyme in patients with renal or hepatic impairment have not been evaluated and no specific dose regimen can be recommended for these patients.
    [Show full text]
  • Transaction Drug 1St (DIN) 2Nd (PIN) 3Rd (PIN) 4Th (PIN) 5Th (PIN) 6Th
    Transaction Drug 1st (DIN) 2nd (PIN) 3rd (PIN) 4th (PIN) 5th (PIN) 6th (PIN) 7th (PIN) 8th (PIN) 9th (PIN) 10th (PIN) 11th (PIN) 12th (PIN) 13th (PIN) Alectinib (Alecensaro®) 02458136 00904400 − − − − − − − − − − − 150 mg capsule Alemtuzumab (LemtradaTM) 02418320 00904161 00904162 00904163 00904164 00904165 00904166 00904167 − − − − − 12 mg / 1.2 mL single-use vial Asfotase alfa (Strensiq®) 02444615 00904483 00904484 00904485 − − − − − − − − − 18 mg / 0.45 mL single-use vial Asfotase alfa (Strensiq®) 02444623 00904486 00904487 00904488 00904489 00904490 − − − − − − − 28 mg / 0.7 mL single-use vial Asfotase alfa (Strensiq®) 02444631 00904491 00904492 00904493 − − − − − − − − − 40 mg / 1 mL single-use vial Asfotase alfa (Strensiq®) 02444658 00904494 00904495 00904496 00904497 00904498 00904499 00904500 00904501 00904502 00904504 00904505 − 80 mg / 0.8 mL single-use vial Canakinumab (Ilaris®) 150 mg/mL powder for solution 02344939 00904404 00903809 00904410 − − − − − − − − − for injection Canakinumab (Ilaris®) 02460351 00904405 00904411 00904412 − − − − − − − − − 150 mg/mL solution for injection Ceftolozane / Tazobactam 02446901 00904433 − − − − − − − − − − − (Zerbaxa®) 1 g / 0.5 g vial Cerliponase Alfa (Brineura®) 150 mg / 5 mL solution for 02484013 00904634 00904635 00904636 − − − − − − − − − intracerebroventricular infusion Cladribine (MavencladTM) 02470179 00904524 00904525 00904526 00904642 − − − − − − − − 10 mg tablet Cysteamine (ProcysbiTM) 02464713 00904354 00904355 − − − − − − − − − − 75 mg delayed-release capsule Daclastavir (DaklinzaTM)
    [Show full text]
  • Sebelipase Alfa) Injection, for Intravenous Use And/Or Antihistamines May Prevent Subsequent Reactions in Those Cases Initial U.S
    HIGHLIGHTS OF PRESCRIBING INFORMATION -----------------------WARNINGS AND PRECAUTIONS------------------­ • Hypersensitivity Reactions including Anaphylaxis: Observe patients These highlights do not include all the information needed to use during and after the infusion. Consider interrupting the infusion or KANUMA safely and effectively. See full prescribing information lowering the infusion rate, based on the severity of the reaction. If a for KANUMA. severe hypersensitivity reaction occurs, immediately stop the infusion and initiate appropriate treatment. Pre-treatment with antipyretics KANUMA (sebelipase alfa) injection, for intravenous use and/or antihistamines may prevent subsequent reactions in those cases Initial U.S. Approval: 2015 where symptomatic treatment is required. (5.1) • Hypersensitivity to Eggs or Egg Products: Consider the risks and ----------------------------INDICATIONS AND USAGE---------------------­ benefits of treatment in patients with known systemic hypersensitivity KANUMA™ is a hydrolytic lysosomal cholesteryl ester and reactions to eggs or egg products. (5.2) triacylglycerol-specific enzyme indicated for the treatment of patients with a diagnosis of Lysosomal Acid Lipase (LAL) deficiency. (1) ------------------------------ADVERSE REACTIONS-------------------------­ The most common adverse reactions are: ----------------------DOSAGE AND ADMINISTRATION-----------------­ Patients with Rapidly Progressive LAL Deficiency Presenting within the • Patients with Rapidly Progressive Disease Presenting within the First 6 First 6 Months of Life: The recommended starting dosage is 1 mg/kg as an Months of Life (≥30%): diarrhea, vomiting, fever, rhinitis, anemia, intravenous infusion once weekly. For patients who do not achieve an cough, nasopharyngitis, and urticaria. (6.1) optimal clinical response, increase to 3 mg/kg once weekly. (2.1) • Pediatric and Adult Patients (≥8%): headache, fever, oropharyngeal Pediatric and Adult Patients with LAL Deficiency: The recommended pain, nasopharyngitis, asthenia, constipation, and nausea.
    [Show full text]
  • Vpriv-Pm-En.Pdf
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrVPRIV® velaglucerase alfa Powder for Solution for Injection 400 U/vial, Intravenous Enzyme Replacement Therapy ATC code: A16AB10 Takeda Canada Inc. Date of Initial Approval: 22 Adelaide Street West, Suite 3800 October 1, 2010 Toronto Ontario M5H 4E3 Date of Revision: December 21, 2020 Submission Control No: 241844 VPRIV® and the VPRIV Logo® are registered trademarks of Shire Human Genetic Therapies, Inc. TAKEDA™ and the TAKEDA Logo® are trademarks of Takeda Pharmaceutical Company Limited, used under license. Page 1 of 24 RECENT MAJOR LABEL CHANGES Warnings and Precautions, Immunogenicity (8) 9/2020 Warnings and Precautions, Infusion-Related Reactions (8) 9/2020 Warnings and Precautions, Breast-feeding (8.1.2) 9/2020 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ................................................................. 4 1 INDICATIONS .................................................................................................................4 2 CONTRAINDICATIONS ..................................................................................................4 4 DOSAGE AND ADMINISTRATION ................................................................................ 4 4.1 Dosing Considerations ..........................................................................................4 4.2 Recommended Dose and Dosage Adjustment ....................................................... 4 4.3 Administration .......................................................................................................4
    [Show full text]
  • 1 LYSOSOMAL ACID LIPASE: from CELLULAR LIPID HANDLER to 2 IMMUNOMETABOLIC TARGET 3 4 5 Gomaraschi M1, Bonacina F2, Norata GD2,3 6 7 1Center E
    1 LYSOSOMAL ACID LIPASE: FROM CELLULAR LIPID HANDLER TO 2 IMMUNOMETABOLIC TARGET 3 4 5 Gomaraschi M1, Bonacina F2, Norata GD2,3 6 7 1Center E. Grossi Paoletti, Department of Excellence of Pharmacological and Biomolecular 8 Sciences (DisFeB); Università Degli Studi di Milano; Milan, 20133, Italy; 2Department of 9 Excellence of Pharmacological and Biomolecular Sciences (DisFeB); Università Degli Studi di 10 Milano; Milan, 20133, Italy; 3SISA Centre; Bassini Hospital; Cinisello Balsamo, 20092, Italy. 11 12 Corresponding author: 13 Professor Giuseppe Danilo Norata 14 Department of Pharmacological and Biomolecular Sciences (DisFeB); Università Degli Studi 15 di Milano; via Balzaretti 9. Milan, 20133, Italy. 16 Phone: 39 0250318313. Email: [email protected] 17 18 19 20 Keywords 21 Lysosomal acid lipase, cholesterol, fatty acids, immune response, enzyme replacement 22 therapy. 1 23 Abstract 24 Lysosomal acid lipase (LAL) hydrolyzes cholesterol esters and triglycerides to free cholesterol 25 and fatty acids,that are then used for the metabolic purposes in the cell. The process also 26 occurs in immune cells which adapt their metabolic machinery to cope with the different 27 energetic requirements associated to cell activation, proliferation and/or polarization. 28 Deficiency of LAL not only causes severe lipid accumulation, but also impacts the 29 immunometabolic signature in animal models. In humans, LAL deficiency has been recently 30 associated with a peculiar clinical immune phenotype, secondary hemophagocytic 31 lymphohistiocytosis. These observations indicate that LAL represents a critical player for 32 cellular immunometabolic modulation and the availability of an effective enzyme replacement 33 strategy makes LAL an attractive target to rewire the immunometabolic machinery of immune 34 cells beyond its role in controlling cellular lipid metabolism.
    [Show full text]